Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Targeting SWI/SNF ATPases in enhancer-addicted human cancers
Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
In silico designing of targeted protein degraders
In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)
